Aclaris Therapeutics Inc
For the period ended Jun 6, 2024. Filed Apr 25, 2024.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 6, 2024 · Filed Apr 25, 2024
ACRS$3.90+8.0%Stored close · as of Nov 6, 2026
Contents
Overview
Compensation for our NEOs is comprised primarily of the following four main components:
| | ||
| Element | | Summary Purpose |
|---|---|---|
| Base Salary | | Provide a fixed source of income commensurate with the NEOs’ positions at the Company |
| Annual Cash Incentive Bonus | | Motivate NEOs to achieve our annual corporate objectives that we believe will translate to long-term stockholder value creation and achievement of our mission |
| Long-term Equity Incentives | | Aid in attraction and retention of NEOs and create stockholder alignment |
| Benefits | | Provide our NEOs with health and welfare benefits, as well as certain protections if we experience a change of control or an NEO separates |
Each of these key elements is further described below, along with the key decisions made for the 2023 plan year.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.